Latest Monoclonal antibodies Stories
CRANBURY, N.J., July 30, 2012 /PRNewswire/ -- Oncobiologics, Inc. announced today a collaboration agreement with XOMA Corporation to develop novel biotherapeutics based on engineering single-chain variable fragments (scFv) into a bi-specific antibody scaffold. Through the partnership, Oncobiologics will utilize XOMA's ADAPT(TM) fully human antibody technology platform as a key component of its drug discovery program. Oncobiologics has selected clinically validated targets that will be...
NEW YORK, July 25, 2012 /PRNewswire/ -- Pharmspective, LLC, the specialty therapeutics market research firm, announced today the release of its two newest syndicated market research reports, Rheumatoid Arthritis Pipeline Perspectives - http://bit.ly/MjeXFo and Psoriasis Pipeline Perspectives - http://bit.ly/PKpqK0 These new Pharmspective reports coincide with a number of key milestones in Rheumatoid Arthritis (RA) & Psoriasis product development: Tofacitinib 2nd line...
NEWARK, N.J., July 25, 2012 /PRNewswire/ -- Actinium Pharmaceuticals Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that the Company made a regulatory milestone payment to Abbott Biotherapeutics Corp. following the launch of Actinium's multi-center Phase I/II clinical trial in acute myeloid leukemia (AML). Acute Myeloid Leukemia is the most difficult form of leukemia to treat. The majority of patients do not qualify...
(Ivanhoe Newswire) - Each year an estimated 70,000 people globally are diagnosed with the kidney immune disorder, idiopathic membranous nephropathy (IMN). Idiopathic membranous nephropathy (IMN) can eventually lead to kidney failure. Standard therapies for IMN can be toxic and lead to further complications, but a new study has discovered the drug rituximab which is commonly used to treat lymphoma and arthritis also benefits patients with IMN. Standard therapy for IMN includes...
Rituximab is more effective and less toxic than standard therapies Highlights: Patients with a particular kidney immune disorder experienced remission when taking the immune drug rituximab, even when standard therapies had failed. Rituximab was safe and well-tolerated by all patients in the study. Each year, an estimated 70,000 people globally are diagnosed with the disorder, called idiopathic membranous nephropathy. A drug commonly used to treat immune disorders such as lymphoma...
ROCKVILLE, Md., July 19, 2012 /PRNewswire/ -- OriGene Technologies, Inc. and Canada's Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) today announced the selection of OriGene Technologies as a major collaboration and development partner to implement blood-based protein assays in heart and kidney transplantation. This multi-year, collaborative project funded by multiple partners will provide monitoring and predictive blood tests, based upon OriGene's extensive...
CARLSBAD, Calif., July 19, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced it has signed a collaborative partnership with the Structural Genomics Consortium (SGC), and several groups of leading expert scientists in antibody technology at the Universities of Chicago and Toronto, to generate a first-ever master set of quality epigenetic recombinant antibodies for use in disease-related research. The first 58 of 200 highly-specific antibodies to be...
NEWARK, N.J., July 19, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. a biotechnology company focused on developing innovative, alpha particle radiotherapy targeted cancer treatments addressing major unmet medical needs, today announced that it has successfully treated the first cohort of patients in a Phase I/II study of Actimab-A(TM) in Acute Myeloid Leukemia (AML) clinical trial. Patients were treated at Memorial Sloan Kettering Cancer Center in New York City....
STAT3 needs to be inhibited to induce immune response in drug-resistant lymphoma Researchers at Moffitt Cancer Center and colleagues have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell non-Hodgkin lymphoma that becomes resistant to treatment, can harness the immune system to eradicate residual malignant cells responsible for disease relapse. Their...
ABBOTT PARK, Ill., July 18, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2012. Diluted earnings per share, excluding specified items, were $1.23, reflecting 9.8 percent growth, exceeding Abbott's guidance range. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $1.08, including specified items. Excluding foreign exchange, worldwide sales increased 6.7 percent. Reported...
